Pharma Spending Gone Bipolar: Generics At One End, Specialty Drugs on the Other
By Jane Sarasohn-Kahn on 23 April 2018 in Amazon, Business and health, Digital health, Digital therapeutics, FDA, Health costs, Health policy, Health politics, Health regulation, Healthcare access, Heart health, media and health, Medication adherence, Medicines, Money and health, Opioids, Pain, Patient experience, Personal health finance, Pharmaceutical, Pharmacy, Prescription drugs, Retail health, Shopping and health, Social networks and health, Specialty drugs, Wearable tech, Wearables

While the use of medicines continues to rise in the U.S., spending grew by only 0.6% in 2017 after accounting for discounts and rebates. In retail and mail-order channels, net spending fell by 2.1%. Prescription drug spending on branded products grew nearly $5 billion less than in 2016; generic drug spending fell by $5.5 billion, according to Medicine Use and Spending in the U.S., a report from the IQVIA Institute for Health Data Science. The report reviews medicines spending in 2017 looking forward to 2022. There were over 5.8 billion prescriptions dispensed in 2017, and generic drugs accounted 90% of





It was an honor to be
January 2027 is in our sights, and that means we're making plans for #CES2027. I've attended the largest consumer electronics show for nearly 20 years, tracking the evolution of digital health which enables people for greater self-care and health agency and literacy. I'm looking forward to collaborating on this webcast with fellow CES experts in their fields to brainstorm what we expect in this
Jane joined host Dr. Geeta "Dr. G" Nayyar and colleagues to brainstorm the value of vaccines for public and individual health in this challenging environment for health literacy, health politics, and health citizen grievance.